148 related articles for article (PubMed ID: 7606879)
61. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients.
Strickland ID; Chaput de Saintonge DM; Boulton FE; Francis B; Roubikova J; Waters JI
Clin Nephrol; 1977 Feb; 7(2):55-7. PubMed ID: 321170
[TBL] [Abstract][Full Text] [Related]
62. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
Tarng DC; Huang TP
Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
[TBL] [Abstract][Full Text] [Related]
63. Iron deficiency anemia and catecholamine metabolism.
Patiroglu T; Dogan P
Indian Pediatr; 1991 Jan; 28(1):51-6. PubMed ID: 2055611
[TBL] [Abstract][Full Text] [Related]
64. Unanticipated favorable effects of correcting iron deficiency in chronic hemodialysis patients.
Pollak VE; Lorch JA; Means RT
J Investig Med; 2001 Mar; 49(2):173-83. PubMed ID: 11288758
[TBL] [Abstract][Full Text] [Related]
65. [Evaluation of iron therapy in patients in long-term haemodialysis (author's transl)].
Serra A; Morlans M; Olmos A; Camps J; Rodríguez JA; Carreras A; Soriano B; Bartolomé J; Piera L
Med Clin (Barc); 1982 Apr; 78(8):313-7. PubMed ID: 7087599
[No Abstract] [Full Text] [Related]
66. [Iron requirements of hemodialysis patients. Serum ferritin as an indicator].
Hunderi OH
Tidsskr Nor Laegeforen; 1986 Apr; 106(9):738-40. PubMed ID: 3705034
[No Abstract] [Full Text] [Related]
67. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.
Patruta SI; Edlinger R; Sunder-Plassmann G; Hörl WH
J Am Soc Nephrol; 1998 Apr; 9(4):655-63. PubMed ID: 9555668
[TBL] [Abstract][Full Text] [Related]
68. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium.
Kooistra MP; Niemantsverdriet EC; van Es A; Mol-Beermann NM; Struyvenberg A; Marx JJ
Nephrol Dial Transplant; 1998 Jan; 13(1):82-8. PubMed ID: 9481720
[TBL] [Abstract][Full Text] [Related]
69. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2242-4. PubMed ID: 17889151
[TBL] [Abstract][Full Text] [Related]
70. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.
Sezer S; Ozdemir FN; Yakupoglu U; Arat Z; Turan M; Haberal M
Artif Organs; 2002 Apr; 26(4):366-70. PubMed ID: 11952508
[TBL] [Abstract][Full Text] [Related]
71. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients.
Driss F; Vrtovsnik F; Katsahian S; Michel C; Baron G; Kolta A; Sedrati N; Mentré F; Mignon F; Cabantchik I; Grandchamp B
Nephron Clin Pract; 2005; 99(3):c63-7. PubMed ID: 15640610
[TBL] [Abstract][Full Text] [Related]
72. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents.
Roe DJ; Harford AM; Zager PG; Wiltbank TB; Kirlin L; Della Valle AM; Van Wyck DB
Am J Kidney Dis; 1996 Dec; 28(6):855-60. PubMed ID: 8957037
[TBL] [Abstract][Full Text] [Related]
73. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
De Marchi S; Cecchin E
Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
[TBL] [Abstract][Full Text] [Related]
74. Evaluation and treatment of iron deficiency in patients with kidney disease.
Bickford AK
Nutr Clin Care; 2002; 5(5):225-30. PubMed ID: 12455224
[TBL] [Abstract][Full Text] [Related]
75. Circulating transferrin receptor during erythropoietin medication of anemic patients with rheumatoid arthritis.
Pettersson T; Teppo AM; Siimes MA
Scand J Rheumatol; 1996; 25(5):321-4. PubMed ID: 8921926
[TBL] [Abstract][Full Text] [Related]
76. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron.
Sturm B; Laggner H; Ternes N; Goldenberg H; Scheiber-Mojdehkar B
Kidney Int; 2005 Mar; 67(3):1161-70. PubMed ID: 15698458
[TBL] [Abstract][Full Text] [Related]
77. A trial of oral iron in dialysis patients.
Strickland ID; Chaput de Saintonge DM; Boulton FE; Brain AJ; Goodwin FJ; Marsh FP; Zychova Z
Clin Nephrol; 1974; 2(1):13-7. PubMed ID: 4595978
[No Abstract] [Full Text] [Related]
78. Hypotransferrinemia of chronically hemodialyzed patients.
Kirschbaum B
Artif Organs; 1999 Dec; 23(12):1047-54. PubMed ID: 10619922
[TBL] [Abstract][Full Text] [Related]
79. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency.
Gasché C; Reinisch W; Lochs H; Parsaei B; Bakos S; Wyatt J; Fueger GF; Gangl A
Dig Dis Sci; 1994 Sep; 39(9):1930-4. PubMed ID: 8082499
[TBL] [Abstract][Full Text] [Related]
80. Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers.
Lainé F; Laviolle B; Ropert M; Bouguen G; Morcet J; Hamon C; Massart C; Westermann M; Deugnier Y; Loréal O
Eur J Appl Physiol; 2012 Apr; 112(4):1391-7. PubMed ID: 21818622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
